Parenteral fat emulsions based on olive and @entity1460 oils: a randomized clinical trial in preterm XXXX .

@entity1 @entity5204 @entity9984 @entity270 @entity1426 @entity1474 @entity1881 @entity1234 @entity412 @entity4722 @entity1460 @entity1718 @entity1865
OBJECTIVE: To evaluate in premature @entity1 a new parenteral lipid emulsion based on olive and @entity1460 oils (ratio 4:1), with less @entity1474 ( @entity5204 ) and more @entity1881 than standard @entity1460 oil emulsion. STUDY DESIGN: Premature @entity1 (gestational age, 28-<37 weeks) were randomized to receive one of the two emulsions within the first 72 hours of life. The @entity412 dose was increased to 2 g/kg/day within 3 days. Plasma phospholipid @entity1718 , @entity1881 /lipid ratio, and urinary @entity1234 ( @entity1865 ) excretion were determined at baseline and after 7 days. RESULTS: Of 45 recruited @entity1 , 33 completed the study per protocol (15 @entity1460 oil, 18 olive oil emulsion). At study end, groups did not differ in plasma phospholipid @entity1426 , total n-6 and n-3 metabolites, but the olive oil group showed higher values of the @entity5204 intermediates @entity9984 (0.19% +/- 0.01% vs. 0.13% +/- 0.02%, P < 0.05) and C20:3n-6 (2.92% +/- 0.12% vs. 2.21% +/- 0.17%, P = 0.005). The plasma @entity1881 /total lipd ratio was higher in the olive oil group (2.45 +/- 0.27 micromol/mmol vs. 1.90 +/- 0.08 micromol/mmol, P = 0.001), whereas urinary @entity1865 excretion did not differ. CONCLUSION: The lower @entity5204 supply with the olive/ @entity1460 oil emulsion appears to enhance @entity4722 conversion. The reduced @entity5204 content, combined with a higher antioxidant intake in the olive oil group, results in an improved @entity270 status. The olive oil-based emulsion is a valuable alternative for parenteral feeding of preterm @entity1 who are often exposed to oxidative stress, while their antioxidative defense is weak.
